ACE SE0010573113

Report

Delayed Nasdaq Stockholm - 05/27 11:24:03 am
21.35	SEK		+5.69%

05/11	TRANSCRIPT : Ascelia Pharma AB, Q1 2022 Earnings Call, May 11, 2022	CI
05/11	QUARTERLY REPORT Q1 2022 : Strong Orviglance support from healthcare professionals	AQ
05/11	Ascelia Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2022	CI

News

Press Releases

Official Publications

Sector news

Communiqués de presse de la société ASCELIA PHARMA AB (PUBL)

05/11	QUARTERLY REPORT Q1 2022 : Strong Orviglance support from healthcare professionals	AQ
05/10	Ascelia Pharma's Food Effect Study shows that Orviglance image enhancement of the liver..	AQ
05/05	Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022	AQ
04/11	Ascelia Pharma publishes Annual Report for 2021	AQ
04/05	Notice of annual general meeting in ascelia pharma ab	AQ
04/01	CFO Kristian Borbos to leave Ascelia Pharma	AQ
03/31	Number of shares and votes in Ascelia Pharma AB	AQ
03/31	HC ANDERSEN CAPITAL : Release of new Ascelia Pharma investment case	AQ
03/22	New independent market research says 84% US healthcare professionals likely to use Orvi..	AQ
03/11	Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study	AQ
03/07	Ascelia Pharma suspends clinical activities in Russia	AQ
03/02	Issue and repurchase of series C shares for share saving program	AQ
02/15	Results from Orviglance comparison study to gadolinium accepted for oral presentation a..	AQ
02/10	QUARTERLY REPORT Q4 2021 : Strong data for Orviglance vs. a gadolinium contrast agent	AQ
2021	Ascelia Pharma receives FDA acceptance of IND application for Oncoral clinical trial	AQ
2021	Results from Orviglance comparison study to gadolinium presented at RSNA 2021	AQ
2021	Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB	AQ
2021	QUARTERLY REPORT Q3 2021 : Oncoral – entering clinical collaboration	AQ
2021	ASCELIA PHARMA : Food Effect Study with Orviglance successfully completed	AQ
2021	ASCELIA PHARMA : Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the ..	AQ
2021	QUARTERLY REPORT Q2 2021 : Preparing Oncoral for the next level	AQ
2021	ASCELIA PHARMA : Covid-19 extends recruitment period of SPARKLE study	AQ
2021	ASCELIA PHARMA : Abstract for Orviglance comparison study to gadolinium accepted at the wo..	AQ
2021	ASCELIA PHARMA : receives conditional FDA acceptance for brand name Orviglance	AQ
2021	QUARTERLY REPORT Q1 2021 : US office opened in preparation of launch	AQ
2021	ASCELIA PHARMA : Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 20..	AQ
2021	ASCELIA PHARMA : Number of shares and votes in Ascelia Pharma AB	AQ
2021	ASCELIA PHARMA AB : publishes prospectus regarding admission to trading of newly issued sh..	AQ
2021	ASCELIA PHARMA : Bulletin from the extraordinary general meeting in Ascelia Pharma AB	AQ
2021	ASCELIA PHARMA : Issue and repurchase of series C shares for share saving program	AQ
2021	ASCELIA PHARMA : Notice of annual general meeting in ascelia pharma ab	AQ
2021	ASCELIA PHARMA : Number of shares and votes in Ascelia Pharma AB	AQ
2021	ASCELIA PHARMA : publishes Annual Report for 2020	AQ
2021	ASCELIA PHARMA : Notice of extraordinary general meeting in Ascelia Pharma	AQ
2021	ASCELIA PHARMA : has carried out a directed new share issue raising SEK 200 million	AQ
2021	ASCELIA PHARMA : intends to carry out a directed new share issue	AQ
2021	ASCELIA PHARMA : opens US office in preparation for Mangoral launch	AQ
2021	QUARTERLY REPORT Q4 2020 : Mangoral shows high diagnostic value in new study	AQ
2021	ASCELIA PHARMA : Information regarding transfer of shares in Ascelia Pharma AB from CMC SP..	AQ
2021	ASCELIA PHARMA : presents clinical development plan for Oncoral as a novel chemotherapy	AQ
2020	ASCELIA PHARMA : gets US patent for second generation Mangoral	AQ
2020	ASCELIA PHARMA : New study shows Mangoral's lesion visualization as effective as gadoliniu..	AQ
2020	QUARTERLY REPORT Q3-2020 : Raised market estimate for Mangoral and preparing for market la..	AQ
2020	ASCELIA PHARMA : EMA confirms Mangoral eligible for the centralized regulatory procedure i..	AQ
2020	ASCELIA PHARMA : Upgraded estimate of addressable market for Mangoral to $500-600 million ..	AQ
2020	ASCELIA PHARMA : Invitation to Ascelia Pharma's virtual Capital Markets Day	AQ
2020	ASCELIA PHARMA : First commercial scale manufacturing of Mangoral	AQ
2020	QUARTERLY REPORT Q2-2020 : First participant in the hepatic study	AQ
2020	ASCELIA PHARMA PUBL : Change in number of shares and votes in Ascelia Pharma AB	AQ
2020	ASCELIA PHARMA PUBL : completes a directed new share issue of 4,697,781 shares, raising ap..	AQ
2020	VATOR SECURITIES : Ascelia Pharma: A delay. Fundamentals for Mangoral remain unchanged.	AQ
2020	ASCELIA PHARMA PUBL : Updated SPARKLE timelines due to Covid-19 impact	AQ
2020	INTERIM FINANCIAL REPORT Q1-2020 : First patient enrolled in Phase 3 study SPARKLE	AQ
2020	ASCELIA PHARMA PUBL : Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 M..	AQ
2020	ASCELIA PHARMA PUBL : First participant enrolled in the clinical hepatic impairment study ..	AQ
2020	ASCELIA PHARMA PUBL : Patent for Oncoral approved in Japan	AQ
2020	ASCELIA PHARMA PUBL : publishes Annual Report for the financial year 2019	AQ
2020	ASCELIA PHARMA PUBL : Nomination Committee proposes election of Lauren Barnes to the Board..	AQ
2020	ASCELIA PHARMA PUBL : Correction to press release regarding in change in number of shares ..	AQ
2020	ASCELIA PHARMA PUBL : Change in number of shares and votes in Ascelia Pharma AB	AQ
2020	ASCELIA PHARMA PUBL : Leading Ascelia Pharma through the Covid-19 period	AQ
2020	ASCELIA PHARMA PUBL : Issue and repurchase of series C shares for share saving program	AQ
2020	VATOR SECURITIES : Ascelia Pharma: A rocket roll out is the key to success	AQ
2020	ASCELIA PHARMA PUBL : First patient enrolled in pivotal Phase III clinical study SPARKLE w..	AQ
2020	2019 YEAR-END FINANCIAL REPORT : Sites opened for recruitment to the pivotal Phase III stu..	AQ
2020	ASCELIA PHARMA PUBL : Five sites now opened in the pivotal Phase III clinical study SPARKL..	AQ
2019	ASCELIA PHARMA PUBL : Nomination Committee appointed for AGM 2020 in Ascelia Pharma AB	AQ
2019	ASCELIA PHARMA PUBL : appoints Julie Waras Brogren as Chief Commercial Officer	AQ

Upcoming event on ASCELIA PHARMA AB (PUBL)

05/31/22

European Society of Gastrointestinal and Abdominal Radiology Conference

Company calendar

Upcoming sector events

07/26/22	IQVIA HOLDINGS INC. : Interim 2022 Earnings Release (Projected)
07/27/22	LONZA GROUP AG : Interim 2022 Earnings Release (Projected)
07/28/22	SEAGEN INC. : Interim 2022 Earnings Release (Projected)
08/10/22	MODERNA, INC. : Interim 2022 Earnings Release (Projected)

More events

Sector

Healthcare
	Pharmaceuticals & Medical Research
		Biotechnology & Medical Research
			Biotechnology & Medical Research
				Other Biotechnology & Medical Research